Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

Bedoukian

Bedoukian Research Inc.

Premium
Consumer Goods

A three-year employee trend is not publicly disclosed. The aggregator figures suggest growth from about 80 in 2017 to somewhere above 100 by 2025, but the sources use different methods and should not be read as a series. Bedoukian Research is a small, family-owned US maker of high-impact aroma chemicals, founded in 1972 and based in Danbury, Connecticut. It does not compete with the large flavor and fragrance houses in compounding. It sells single molecules to them and to other formulators: unsaturated aldehydes, leaf-alcohol derivatives, lactones, jasmonoids and similar materials that work at low dose. A second brand, BedoukianBio, applies the same multi-step organic synthesis to insect pheromones and repellent actives. A third activity is custom and toll manufacturing for pharmaceutical, biotech and agrochemical clients. The company's edge is chemistry depth and speed: R&I reports directly to the CEO and sits next to the plant. Its constraints are scale, a single manufacturing site and limited disclosure. Since the death of long-time president Dr. Robert Bedoukian in August 2024, the company has moved to professional management, appointing a non-family CEO in October 2025. --- **The company's own description.** There is no annual report. The closest equivalent is the boilerplate in the 18 May 2026 press release, which describes a family-owned specialty chemical company founded in 1972 and headquartered in Danbury. It supplies aroma chemicals and blends for flavor, fragrance and personal care under the Bedoukian Flavor & Fragrance brand, and provides custom manufacturing for pharmaceutical, biotech and agrochemical clients. The October 2025 CEO announcement adds semiochemicals as a second served industry alongside flavor and fragrance. **Independent characterization.** Bedoukian is an upstream ingredient manufacturer. It sits between commodity and fine-chemical feedstock suppliers and the compounders (flavor and fragrance houses) that blend ingredients into finished flavors and perfumes for consumer goods companies. Its catalog is weighted to "high-impact" molecules, meaning materials used at fractions of a percent in a formula. The 2026 featured fragrance list shows recommended odor evaluation levels of 0.1% to 10%. This positions the company in low-volume, high-value specialties, where purity, isomer control and reliable supply matter more than tonnage. **Revenue model.** All evidence points to product sales (merchant sale of molecules by the kilogram) plus fee-based custom synthesis and toll processing. There is no indication of subscription or licensing revenue. Repellent actives are patented and offered as ingredients for others' formulations, which could involve licensing, but no licence terms are disclosed. The revenue mix across flavor, fragrance, pheromones and custom work is not publicly disclosed. **Value chain position.** **End-markets.** Per the company: food and beverage flavors, fine fragrance, personal care, home care and air care; agricultural, forestry, residential and stored-product pest management through BedoukianBio; and pharmaceutical, biotech, agrochemical and specialty chemical custom manufacturing. **Catalog size: conflicting figures.** Sources differ and the discrepancy should be noted, not resolved by guesswork: The differences probably reflect definitions (all catalog items versus actively promoted molecules), but this is not confirmed.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1972
Connecticut, US

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
DaburIndia

Dabur India Limited

Premium
Healthcare

Dabur India is India's fourth-largest listed FMCG company by its own description, and the world's largest Ayurveda-based consumer products business. Founded in 1884, it converts a 140-year-old Ayurvedic heritage into a modern portfolio of eight Power Brands (Dabur Chyawanprash, Dabur Honey, Honitus, PudinHara, Dabur Lal Tail, Dabur Amla, Dabur Red Paste and Réal) and a long tail of category leaders such as Hajmola, Vatika, Odonil, Odomos, Meswak and Badshah spices. Its products reach roughly eight of ten Indian households, and it sells in over 120 countries through 21 manufacturing facilities. FY2026 consolidated revenue was ₹13,193 cr with an 18.6% operating margin and ₹1,869 cr of attributable profit. About 27% of revenue is international. The investment case rests on natural/herbal tailwinds, rural reach and cash generation, offset by a decade of mid-single-digit growth, a de-rating, and US product-liability exposure. | Field | Detail | |---|---| | Legal name | Dabur India Limited | | Former names | Corporate-history databases record incorporation in 1975 as Vidogum Ltd, later renamed Dabur India Ltd | | Founded | 1884, Calcutta (Kolkata), by Dr. S.K. Burman; the brand name is a portmanteau of "Daktar" (doctor) and "Burman" | | Incorporation jurisdiction | India (Companies Act) | | Registered office | 8/3, Asaf Ali Road, New Delhi 110002, India (FY2025-26 Annual Report, Corporate Information) | | Corporate headquarters | Dabur Corporate Office, Kaushambi, Sahibabad, Ghaziabad 201010, Uttar Pradesh, India | | International hub | Dabur International Ltd, Dubai, UAE (international business HQ) | | Stock exchanges & tickers | BSE: 500096; NSE: DABUR; Bloomberg: DABUR:IN | | ISIN | INE016A01026 | | CUSIP | Not applicable (no US listing) | | Face value | ₹1 per share; approximately 177.3 crore shares outstanding | | Fiscal year end | 31 March | | Statutory auditor | G. Basu & Co. (FY2025-26 Annual Report) | | Internal auditor | PricewaterhouseCoopers Services LLP | | Website | www.dabur.com | | Market capitalisation | ₹67,171 cr at ₹379 close on 5 October 2026 (Screener) | | Promoter holding | 66.24% (June 2026 shareholding pattern); no promoter pledge reported | | Credit ratings | CRISIL AAA/Stable and A1+ (reaffirmed 20 Nov 2025); ICRA AAA/Stable and A1+ (reaffirmed 12 Mar 2026) | | Chairman | Mohit Burman (non-executive, promoter family) | | Global CEO | Mohit Malhotra (Whole-Time Director & Global CEO since 17 Feb 2026) | | CEO – India Business | Herjit S. Bhalla (joined 23 Apr 2026) | | CFO | Ankush Jain (CFO since 1 April 2021 per MarketScreener; not reconfirmed in the FY2026 report pages reviewed) | The entity profiled is Dabur India Limited, the listed Indian FMCG and Ayurvedic healthcare company controlled by the Burman family. The name and type supplied ("Dabur India Ltd.", "Public company") match exactly: the company is actively listed on both major Indian exchanges and is a constituent of the BSE 200, BSE 500, Nifty 500 and BSE FMCG indices, and is in the NSE F&O segment. Employee counts are reported inconsistently across sources and are not consistently disclosed on a consolidated basis in the materials reviewed. MarketScreener lists 4,768 employees (appears to be a standalone permanent-employee figure from a prior BRSR), while Tracxn reports 10,677 employees as of 31 May 2026 (likely consolidated, including international subsidiaries). Both figures are presented with this discrepancy flagged. --- ### What the company does Dabur manufactures, markets and distributes branded fast-moving consumer goods with a strong natural and Ayurvedic positioning. Its business spans four broad domestic verticals and an international business: **Healthcare:** Health supplements (Dabur Chyawanprash, Dabur Honey, Dabur Glucose, Shilajit), digestives (Hajmola, PudinHara), OTC and ethicals (Honitus cough and cold, Dabur Lal Tail baby massage oil, classical Ayurvedic medicines). **Home & Personal Care (HPC):** Oral care (Dabur Red Paste, Meswak, Babool), hair care (Dabur Amla, Vatika, Anmol and Sesa hair oils, Vatika shampoos), skin care (Gulabari, Fem, Oxylife), and home care (Odonil air fresheners, Odomos mosquito repellent, Sanifresh toilet cleaner). **Foods & Beverages:** Réal fruit juices and nectars, Réal Activ functional beverages and coconut water, Hommade culinary pastes, Badshah ground and blended spices, and new carbonated/flavoured drinks (Réal Cheers). **International:** Operations in the Middle East and North Africa (MENA), Sub-Saharan Africa (SSA), Turkey (Hobi), the United States (Namaste Laboratories, ethnic hair care), the UK and Europe, Bangladesh, Nepal and other South Asian markets. **Retail and others:** A small retail segment and an "others" segment covering guar gum, pharma and miscellaneous businesses. ### Company's own description In its press releases and FY2025-26 Annual Report, Dabur describes itself as "India's leading science-based Ayurveda major" and one of India's leading FMCG companies, with eight distinct Power Brands. The FY2026 strategy section states that its flagship brands (Dabur Red, Réal, Dabur Chyawanprash, Dabur Honey, Hajmola, Dabur Amla, Odonil and Vatika) contribute over 70% of revenue. The FY2026 AGM presentation positioned the company as one of India's top four FMCG companies, with products in 8 out of 10 households and 27% international revenue saliency, and noted that e-commerce contributed about 9% of the business. ### Business and revenue model | Revenue type | Share of revenue | Comment | |---|---|---| | Branded product sales (FMCG) | ~99% | Consumer Care + Food segments (FY2026: ₹12,880 cr of ₹13,193 cr, derived) | | Retail operations | ~0.8% | Retail segment, ₹107 cr in FY2026 | | Other (guar gum, pharma, others) | ~1.3% | ₹167 cr in FY2026 | | Services / subscription / licensing | Not material | Not separately disclosed | Dabur's revenue model is overwhelmingly product sales of branded consumer goods; there is no material service, subscription or licensing revenue. Revenue is recognised on sale to distributors, modern-trade accounts, e-commerce platforms and institutional buyers, net of trade schemes and discounts (scheme netting is material; ICRA noted "optical gross margin dilution from higher scheme netting in competitive categories" in FY2026). ### Value-chain position Dabur is a vertically integrated brand owner. Upstream, it sources herbs and agricultural inputs (including through its own cultivation programmes covering 15,567 acres of medicinal and aromatic plants in FY2026), honey, fruit pulp/concentrates, edible oils (coconut/mustard), and petrochemical-derived inputs (plastics, LLP, SLES). Midstream, it manufactures in 12–13 proprietary Indian plants plus 81+ third-party manufacturing units (FY2026 Annual Report, logistics section) and 8 overseas markets. Downstream, it distributes through 3 mother warehouses and 26 C&F agents to a network of distributors and stockists covering general trade (kirana stores, chemists), modern trade, e-commerce and quick commerce, and a rural sub-stockist network. ### Customers and end-markets Direct customers are distributors, super-stockists, modern-trade chains, e-commerce/quick-commerce platforms (Amazon, Flipkart, Blinkit, Zepto, Swiggy Instamart and others), institutional and CSD (Canteen Stores Department) channels, and export distributors. End consumers span urban and rural India, with rural demand outpacing urban for 18 consecutive quarters as of Q1 FY2027 (CEO commentary, July 2026). End-markets include oral care, hair oils, shampoos, skin care, air fresheners, mosquito repellents, health supplements, digestives, OTC medicines, juices and spices. ### Independent characterisation Dabur is best understood as a natural/Ayurveda-anchored mid-cap FMCG company with a defensible but slowly growing core and an above-average international mix. Its moat lies in category leadership in niches where large multinationals are weaker (chyawanprash, honey, digestives, herbal toothpaste, hair oils), deep rural distribution, and Ayurvedic credibility. Its weaknesses are a revenue CAGR of only about 6.6% over FY2021–FY2026, a beverages business vulnerable to weather and competition from carbonated drinks, and a recent tendency to post headline growth below peers such as Marico, which overtook Dabur in revenue in FY2026 (₹13,611 cr vs ₹13,193 cr). The business is highly cash generative (operating cash flow of ₹2,579 cr in FY2026, 122% of operating profit per Screener) and essentially net-cash, giving it optionality for M&A that it is now deploying through Dabur Ventures and bolt-on acquisitions.

Revenue$1.5B
EmployeesN/A
Market CapN/A
Founded1884
New Delhi, India
Yamaha

Yamaha Motorsports, USA

Premium
Automotive

Yamaha Motorsports USA as a wholly owned subsidiary (Yamaha Motors) responsible for sales, marketing, and distribution of powersports and utility vehicles across North America. The parent company is publicly listed on the Tokyo Stock Exchange (7272) and reported consolidated net sales of approximately ¥2.4 trillion (roughly $16 billion USD) for fiscal year 2024. Within the heavy Equipment and Utility Vehicles Market, Yamaha's U.S. subsidiary functions as a critical commercial arm, channeling the parent's engineering output—developed across manufacturing facilities in Japan, the United States (Newnan, Georgia), and multiple Asian markets—into one of the world's largest utility vehicle consumer bases. Yamaha's core portfolio in the heavy Equipment and Utility Vehicles Market centers on its WOLVERINE and VIKING side-by-side utility vehicle (UTV) lines, which compete directly against Polaris RANGER, Can-Am Defender, and John Deere Gator platforms. The WOLVERINE RMAX series targets recreational and light-duty work applications with two- and four-seat configurations, while the VIKING VI offers a six-seat layout aimed at agricultural, ranch, and municipal fleet operators. Yamaha differentiates its UTV lineup through its proprietary Ultramatic continuously variable transmission, independent rear suspension across most trim levels, and a reputation for drivetrain durability built on decades of ATV manufacturing. The company distributes through an authorized dealer network exceeding 2,700 locations across the United States, providing service infrastructure that supports fleet and commercial buyers. Yamaha Motor Co. has directed strategic investment toward electrification and connectivity within the utility vehicle segment. The parent company announced a medium-term management plan through 2026 that allocates capital toward electric powertrain development for off-road and utility applications, with prototype electric UTVs demonstrated at industry events. Yamaha also maintains a long-standing OEM and technology-sharing relationship with Polaris Industries—most notably a historical engine supply arrangement—though competitive dynamics in the UTV segment have evolved as both companies expanded proprietary platforms. In the U.S. market, Yamaha has pursued dealer network expansion and fleet sales programs targeting government agencies, agricultural operations, and resort/hospitality operators as distinct commercial segments within the broader utility vehicle category. Yamaha's utility vehicle segment competes in a North American UTV market that industry sources place among the fastest-growing powersports categories, with Polaris and Can-Am (BRP) holding the largest volume shares and Yamaha occupying a consistent third-to-fourth position by unit sales. The WOLVERINE RMAX4 1000 and VIKING VI remain the flagship revenue contributors within Yamaha's U.S. utility vehicle portfolio. Commercial and government fleet buyers—including national park services, agricultural cooperatives, and resort operators—represent a growing share of Yamaha's UTV sales mix, reflecting the company's deliberate push beyond purely recreational buyers toward higher-margin, repeat-purchase institutional customers.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1976
Cypress, California, USA (U.S. subsidiary); Iwata, Shizuoka, Japan (Parent)
Suzuki

Suzuki Motor USA

Premium
Automotive

Suzuki Motor Corporation, founded in 1909 in Hamamatsu, Japan, established Suzuki Motor USA as its North American subsidiary to distribute and support its diverse vehicle lineup across the United States. The parent corporation operates manufacturing and sales networks across more than 200 countries and territories, with consolidated global operations spanning automobiles, motorcycles, marine engines, and all-terrain utility vehicles. Within the heavy Equipment and Utility Vehicles Market, Suzuki Motor USA functions as the primary conduit for the parent company's off-road and utility-oriented product lines into the North American market, drawing on Suzuki Motor Corporation's vertically integrated manufacturing base in Japan, India, and Southeast Asia. Suzuki Motor USA's core portfolio relevant to the heavy Equipment and Utility Vehicles Market centers on its KingQuad series of all-terrain vehicles (ATVs), which are positioned as workhorse utility platforms for agricultural, recreational, and light industrial applications. The KingQuad lineup — spanning engine displacements from 400cc to 750cc — competes directly against Polaris, Can-Am, and Honda in the utility ATV segment, differentiating on powertrain reliability, four-wheel-drive capability, and towing capacity. Suzuki's utility ATVs are distributed through a dealer network across the United States, targeting rural landowners, farmers, and outdoor recreation consumers who require dependable load-bearing and terrain-traversal performance. Suzuki Motor Corporation's strategic direction for its utility vehicle segment has emphasized product refinement over aggressive platform expansion, with the KingQuad 750AXi remaining the flagship utility ATV and receiving incremental updates to fuel injection calibration and suspension tuning rather than full generational redesigns. The parent company has not announced major acquisitions specifically targeting the North American utility vehicle space in recent years; instead, Suzuki has maintained partnerships with its established dealer and distribution networks to sustain market presence. Suzuki Motor Corporation's broader corporate strategy, as outlined in its annual reports, prioritizes compact vehicle segments and emerging markets, which constrains the capital allocation directed toward expanding the North American high-equipment and utility vehicle lineup. Suzuki's KingQuad series retains a loyal customer base among agricultural operators and rural utility users in the United States, though the brand holds a smaller share of the North American utility ATV market compared to segment leaders Polaris and Can-Am. The utility ATV segment represents a niche but stable revenue contributor for Suzuki Motor USA, supported by aftermarket parts, accessories, and dealer service revenue.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1909
Brea, California, USA
TAT

TAT SENG Packaging Group Ltd.

Premium
Equipment & Machinery

Tat Seng Packaging Group is a mid-sized, controlled, Singapore-domiciled corrugated packaging converter whose economic centre of gravity lies in East China. It manufactures corrugated boards and converted boxes (regular slotted cartons, die-cut, offset-printed, heavy-duty and partition formats) to customer specification, supplemented by traded ancillary packaging consumables. Roughly 82% of FY2025 revenue of S$231.4 million came from five PRC plants in Jiangsu, Anhui and Tianjin, with the balance from a single Singapore operation at Senoko. The group's customers are multinational and local manufacturers, led by food and beverage (about 42% of FY2025 sales). It is a price-taker in a structurally oversupplied Chinese market, with thin but positive margins (FY2025 net margin 7.3%), a historically net-cash balance sheet, and a shareholder register dominated by Dr Goi Seng Hui's group (about 89%). Its 2026 S$0.39 special-plus-final dividend redistributed roughly half of its cash, redefining it from a cash-rich value stock into a leaner, yield-oriented holding. --- ### What the company does Tat Seng designs, manufactures and sells corrugated paper packaging products made to customer specifications, and also distributes a range of packaging-related consumables [SGXCI; FY25R Note 1]. The group's principal activity, as stated in its financial statements, is the manufacture and sale of corrugated paper products and other packaging products [FY25R]. All revenue is recognised at a point in time on transfer of goods; there is no service, subscription or licensing revenue line [FY25R Note 4.2]. The company's stated vision is "To be the preferred corrugated packaging solution provider" [AR25]. Its mission statement emphasises win-win solutions for customers, employee growth, shareholder value creation and care for community and environment [AR25]. ### Business and revenue model | Dimension | Characterisation | Evidence | |---|---|---| | Revenue model | ~100% product sales; make-to-order corrugated packaging plus traded ancillary items | FY25R Note 4.2 (point-in-time revenue only) | | Product vs service mix | Product: ~100%; service, subscription, licensing: nil disclosed | FY25R | | Value-chain position | Mid-stream converter: buys containerboard (linerboard, corrugating medium) from paper mills, runs corrugators to make board, and converts board into boxes; does not appear to own containerboard mills | Inferred from product descriptions and raw-material commentary in FY25R/AR25; no paper mill disclosed in group structure | | Pricing dynamic | Cost-plus with lag; selling prices pressured by PRC overcapacity, raw-material (paper) costs pass through imperfectly | FY25R Section 4 commentary; AR25 outlook | | Customer types | Multinational corporations (MNCs) and local manufacturers | SGXCI; AR25 | | Volume metric | Sales volume in square metres (sqm) of board/cartons, reported by geography | FY25R; H126 | ### End markets served (FY2025 sales by customer sector) | Customer sector (as extracted from AR25 chart) | FY2024 share (%) | FY2025 share (%) | |---|---|---| | Food & Beverage | 41 | 42 | | Medical & Healthcare, Pharmaceutical & Chemical | 29 | 26 | | Printing, Publishers & Converters | 14 | 15 | | Electronics & Electrical | 9 | 10 | | Others | 7 | 7 | The annual report presents a sales-by-customer-sector chart [AR25 p.5]. Food & Beverage is the largest sector. The text extraction of the chart lists categories and percentages in the following order; the mapping of the four smaller categories should be verified against the printed graphic. Third-party profiles also cite plastic and metal stamping and other export-related manufacturing as served industries [YF profile]. ### Independent characterisation Tat Seng is best understood as a regional B2B industrial converter with three defining economic features. First, it is geographically concentrated in the Yangtze River Delta (Suzhou, two Nantong sites) plus Hefei and Tianjin, where it competes against far larger integrated paper groups and thousands of small local box plants; its PRC gross margin is therefore dictated by containerboard prices and regional capacity utilisation rather than product differentiation. Second, its Singapore operation is small (S$42.3 million FY2025 revenue) but historically the balance-sheet anchor, holding most of the group's treasury assets (Singapore segment assets S$145.3 million at end-FY2025 versus segment revenue of S$42.3 million) [FY25R Note 4.1]. Third, earnings quality is heavily influenced by non-operating items: net finance income contributed S$2.5 million of FY2025's S$20.9 million pre-tax profit (12%), and PRC tax incentives (High and New Technology Enterprise status) materially affect after-tax returns [FY25R; AR25].

Revenue$0.2B
EmployeesN/A
Market CapN/A
Founded1968
Singapore
Teijin

Teijin Limited

Premium
Automotive

Teijin is a 108-year-old Japanese materials-and-healthcare group in the middle of the most radical portfolio reconstruction in its history. Having sold its IT arm (INFOCOM, ¥134.4 bn, 2024), its North American automotive composites business (2025) and its aramid-paper joint-venture stakes (to DuPont, 2026), Teijin has shrunk from a ¥1 trillion-revenue conglomerate to an ¥873 bn group in FY2025, absorbing ¥95.2 bn and ¥88.9 bn of impairments in consecutive years. From April 2026 it reports four segments: Apparel & Industries (the polyester-centric trading/manufacturing platform, enlarged on 1 October 2026 into TA Frontier with Asahi Kasei), Healthcare & Life Solutions (Japanese home healthcare and rare-disease pharma), Electronics & Energy (polycarbonate resins, battery separators, semiconductor membranes), and Specialty Materials (Twaron aramid, Tenax carbon fibre, composites — now explicitly a turnaround unit). Management's FY2028 targets — ¥60 bn adjusted operating income and 8% ROE — imply more than doubling FY2025 profit, largely through structural reform rather than volume growth. --- ### What Teijin does Teijin develops, manufactures, converts and sells polymer-based materials and provides healthcare products and services. Its activities span the full chemical value chain from monomer synthesis (aramid monomers at Delfzijl, Netherlands) through polymerisation, fibre spinning, resin compounding and textile conversion, to finished products and services such as home oxygen therapy and CPAP rental in Japan. **Company self-description (paraphrased from the May 2026 Medium-Term Plan briefing and FY2024 results deck).** Management describes Teijin as moving away from a "material-centric," capital-investment-led model, which it believes has reached its limits as materials commoditise, toward a "Customer-Driven" model. In this model, Teijin combines its tangible assets (materials, plants) and intangible assets (technologies, services, partner networks) to solve customers' latent problems — through *suriawase* (close co-creation with customers before specifications are fixed) and *kumiawase* (combining in-house and third-party technologies, services and partners). Teijin Frontier (textiles) and the home healthcare business are cited internally as the existing proof points of this model. ### Business model and revenue model | Revenue type | Where it arises | Approximate weight (analyst characterisation) | |---|---|---| | Product sales — manufactured materials | Aramid fibres, carbon fibre and prepregs, polycarbonate resin, battery separators, membranes, polyester fibre | Majority of Specialty Materials and Electronics & Energy | | Product sales — traded/converted goods | Textiles, apparel products, industrial textiles, building materials and resin products handled by TA Frontier (manufacturer-cum-trading house) | Majority of Apparel & Industries (~40% of group revenue) | | Service/rental (recurring) | Home oxygen concentrators, CPAP devices rented to patients via Japan's insurance-reimbursed home-care system; maintenance, contact centres, visiting nursing | Core of Healthcare & Life Solutions profit | | Pharmaceutical sales | Rare/intractable-disease drugs; legacy long-listed drugs being divested | Shrinking | | Licensing income | Pharmaceutical out-licensing (cited as a FY2025 profit contributor) | Small, lumpy | The precise product/service/licensing split is not publicly disclosed; the above is an independent characterisation based on segment disclosures. ### Value-chain position and customers **Upstream/integrated producer:** in para-aramid (one of two global leaders with DuPont's former Kevlar business), carbon fibre (one of the three Japanese majors with Toray and Mitsubishi Chemical) and polycarbonate resin. **Midstream converter/trader:** in polyester textiles, where the trading-house function (sourcing, design support, sewing, logistics, import handling) is as important as manufacturing. **Downstream service provider:** in Japanese home healthcare. **Customer types:** tyre and rubber goods makers; optical-fibre cable producers; body-armour and protective-apparel makers and defence agencies; aircraft OEMs and tier-1s (Airbus is publicly identified as a carbon-fibre application customer in Teijin's investor materials); automotive OEMs and suppliers; electronics, office-equipment and battery makers; apparel brands and retailers; construction-material customers (newly added via Asahi Kasei Advance); hospitals, physicians and patients in Japan. **End-markets served (per FY2025 assumptions slide, May 2025):** mobility (automotive, aircraft); infrastructure and industrial (optical fibre, water treatment, power cables, wind power); electrical and electronic equipment (office equipment, electronic devices, batteries, semiconductors); healthcare (pharmaceuticals, home medical devices). ### Independent characterisation Teijin is best understood today as two good businesses, one decent niche business and one large problem. The good businesses — polyester-based Apparel & Industries (FY2025 AOI ¥17.1 bn) and Japanese home healthcare (driving Healthcare AOI of ¥13.4 bn) — are asset-light, service-rich and return above the cost of capital. Electronics & Energy (FY2025 AOI ¥18.9 bn restated) is a profitable but cyclical niche. Specialty Materials (aramid, carbon fibre, composites; FY2025 AOI -¥9.0 bn restated) carries most of the group's capital, most of its impairment history and most of its execution risk. The investment case hinges on whether that segment can be stabilised without further write-downs.

Revenue$5.8B
Employees15,689
Market CapN/A
Founded1918
United States, North America
Reckitt

Reckitt Benckiser Group Plc

Premium
Consumer Goods

| Field | Detail | |---|---| | Entity profiled | Reckitt Benckiser Group plc (trading name "Reckitt"). This is the exact legal-name match. | | Listing status | Public company, confirmed. Listed on the London Stock Exchange Main Market and a FTSE 100 constituent. This matches the type supplied. | | Former names / predecessors | Reckitt & Colman plc and Benckiser N.V. merged in December 1999 to form Reckitt Benckiser plc. Reckitt Benckiser Group plc became the group holding company in a 2007 reconstruction. The corporate brand was changed to "Reckitt" in March 2021. | | Founding | Benckiser roots date to 1823 (Germany). Reckitt & Sons dates to 1840 (Hull, England). The current group was formed in 1999. | | Incorporation jurisdiction | England and Wales (UK) | | Companies House number | 06270876 (from prior knowledge; not re-verified this cycle) | | LEI | 5493003JFSMOJG48V108 | | Registered office / HQ | 103–105 Bath Road, Slough, Berkshire SL1 3UH, United Kingdom (H1 2026 Statement, Note 1) | | HQ discrepancy | Some 2026 press (Alliance News, Q1 2026 coverage) describes the company as "Uxbridge-based". Company filings still cite Slough as the registered office. | | Primary listing / ticker | LSE: RKT | | Other lines | US OTC ADR: RBGLY. US OTC ordinary line: RBGPF. Xetra/Frankfurt: 3RB. Mexican BMV: RB N. | | ISIN | GB00BSZBP530. This is the new ISIN from 2 February 2026, after the 24-for-25 share consolidation. The old ISIN was GB00B24CGK77 (Eurex corporate action notice, Jan 2026). | | CUSIP (ADR) | — | | Nominal value per share | 10 5/12 pence after the consolidation (H1 2026, Note 9) | | Shares in issue | 674,005,752 at 30 Jun 2026, of which 38,950,759 were held in treasury (H1 2026, Note 9). Voting shares were therefore about 635.1m before H2 2026 buybacks. | | Fiscal year end | 31 December | | Auditor | KPMG LLP. In H1 2026 the Board decided to retain KPMG and not proceed with the previously announced move to PwC (H1 2026 Statement). | | Website | www.reckitt.com | | Measure | Value | Source | |---|---|---| | Latest (company) | About 36,000 employees in 80 countries | reckitt.com homepage, 2026, after the Essential Home divestment | | Third-party (Revelio Labs, modelled) | About 43,000 (2023), about 41,700 (2024), about 41,400 (2025) | Revelio Labs, Sep 2025 | | Other aggregators | 35,139 (Morningstar); 37,900 (MarketScreener) | — | The three-year trend is down. Headcount fell from roughly 40,000+ before the July 2024 strategy reset to about 36,000 after the Essential Home carve-out. Drivers were the transfer of six plants and their staff to Advent, management-layer reduction under Fuel for Growth (five layers cut to three), and shared-service consolidation. ### Market capitalisation | Measure | Value | Source | |---|---|---| | Share price | 4,905p (25 Sep 2026 close) | StockAnalysis | | Market cap (implied) | About £31.1bn, using about 635m voting shares | Derived | | Market cap (secondary) | £32.6bn on 28 Aug 2026 at 5,132p | StockAnalysis | | Enterprise value | About £40.5bn | Market cap plus H1 2026 net debt of £9,380m | Reckitt is a UK-headquartered, pure-play consumer health and hygiene company that is part-way through a deliberate portfolio contraction. It owns 11 "Powerbrands" that drive more than 80% of Core net revenue: Dettol, Lysol, Harpic, Finish, Vanish, Durex, Veet, Mucinex, Nurofen, Strepsils and Gaviscon. Since the July 2024 strategy update, Reckitt has done the following: - sold a 70% stake in its £1.9bn-revenue Essential Home household business to Advent International (completed 31 December 2025); - returned £6.4bn to shareholders since July 2024; - cut fixed costs from 20.9% to 19.4% of revenue in one year; - reclassified Mead Johnson Nutrition (£2.1bn revenue) as non-core, with all options open. Core Reckitt grew 5.2% LFL in 2025, at a 26.7% adjusted operating margin. Emerging Markets are now its largest area at 44% of Core revenue in H1 2026. The investment case rests on three things: medium-term 4–5% Core growth, margin expansion, and a clean exit from Mead Johnson. That exit is weighed down by US NEC litigation, although the defence record has recently been strong. --- ### What the company does | Unit | Contents | Share of revenue | |---|---|---| | Core Reckitt | Four product categories (Self Care, Germ Protection, Household Care, Intimate Wellness), managed through three geographic Areas (Emerging Markets, Europe, North America) | 80% of H1 2026 Group revenue | | Mead Johnson Nutrition (MJN) | Infant and child nutrition (Enfamil, Nutramigen). Designated non-core. | 17% of H1 2026 Group revenue | | Vestacy Transitional Services | Low-margin transitional manufacturing and distribution for the divested Essential Home business, now named Vestacy. Expected to run off as separation completes. | £235m revenue in H1 2026 at about 5% gross margin | Reckitt develops, manufactures, markets and sells branded consumer health and hygiene products. Its own description of its purpose is to "protect, heal and nurture in the pursuit of a cleaner, healthier world" (company boilerplate, 2025–26 RNS). In its July 2024 Strategy Update and the FY2024/FY2025 reports, management set the ambition to become a "world-class consumer health and hygiene company" focused on high-growth, high-margin Powerbrands. From 1 January 2026, reported operations are: ### Business and revenue model | Revenue type | Approximate mix | Comment | |---|---|---| | Branded product sales: OTC health, VMS, sexual wellness, hygiene, household | About 96% of H1 2026 Group revenue | Core Reckitt plus MJN | | Transitional services and contract manufacturing (Vestacy) | About 4% of H1 2026 Group revenue | Declining. Very low margin. | | Subscription / licensing | Not material; not separately disclosed | n/a | Reckitt's revenue is almost entirely product sales of branded fast-moving consumer goods (FMCG) and over-the-counter (OTC) medicines. It has: - no material subscription revenue; - no material licensing revenue. Minor brand-licensing income exists in some markets; not separately disclosed. - a small service-type income stream from 2026: transitional manufacturing, distribution and services income from Vestacy (£248m of related-party income in H1 2026 under IAS 24); - vendor loan note interest (£10m in H1 2026); - a share of the Vestacy associate's result (a £23m loss in H1 2026). ### Value-chain position Reckitt is a vertically integrated brand owner. It handles: - R&D, including medical and material science; - regulatory affairs for OTC drugs and infant formula, which are FDA-regulated in the US; - in-house manufacturing across a global plant network, supplemented by co-manufacturers; - brand marketing (Brand Equity Investment was 14.6% of net revenue in FY2025); - sales and distribution to retail customers. It does not own retail. It sells through: - mass grocery and hypermarkets; - drugstores and pharmacies; - e-commerce, which is material in China, where social e-commerce and new online launches drive growth; - traditional trade (kiranas) in India and other emerging markets; - hospital and clinical channels for MJN preterm products and for Biofreeze clinical sales. ### Customer types and end-markets | Customer type | Channel examples | Exposure | |---|---|---| | Mass retailers and grocers | Walmart, Target, Tesco and other major multiples (named retailers not disclosed by share) | Hygiene and household brands | | Pharmacy and drug chains | US drug chains, European pharmacies | Self Care OTC: Mucinex, Nurofen, Strepsils, Gaviscon | | E-commerce platforms | Amazon, Tmall/JD, Douyin and other social commerce | High share in China (Durex, Intima, Move Free, Dettol) | | Traditional trade | India and Africa distributor networks | Dettol, Harpic, Durex | | Healthcare professionals and hospitals | NICUs, paediatricians, clinics | MJN preterm and specialty formulas; Biofreeze clinical | | Governments and programmes | US WIC (Women, Infants and Children) programme contracts | MJN; WIC shipments are lower value per unit | End-markets served: - consumer OTC healthcare (cold and flu, pain, digestive health); - vitamins, minerals and supplements (VMS); - sexual wellness and intimate care; - hair removal; - surface and personal disinfection; - toilet care; - automatic dishwashing; - laundry stain removal; - infant and specialised paediatric nutrition. ### Independent characterisation Reckitt is best understood as a two-speed consumer-health hybrid. Roughly half of Core revenue sits in OTC and VMS ("Self Care") and sexual wellness. These are structurally higher-growth and higher-margin categories with pharmacy-like regulatory moats. The other half sits in hygiene and household categories (Germ Protection and Household Care). These carry strong brand shares but face private-label and promotional pressure, especially autodish in Europe. The 2024–2026 programme has three parts: - removing the lowest-growth home-care tail (Essential Home); - ring-fencing the litigated nutrition asset (MJN); - funding brand investment through fixed-cost reduction. The mix shift toward Emerging Markets is pronounced. Emerging Markets delivered LFL growth of 14.6% in FY2025 and 8.5% in H1 2026, which makes the group more growth-geared but also more exposed to FX, geopolitical shocks (Middle East, Russia) and Chinese tax and regulatory changes such as the VAT on condoms.

Revenue$18.7B
EmployeesN/A
Market CapN/A
Founded1823
Slough, United Kingdom
Aspen

Aspen Holdings

Premium
Healthcare

Aspen Group is an internally managed, ASX-listed owner, operator and developer of affordable accommodation in Australia. It targets households earning less than A$100,000 a year that need rents below about A$500 per week, a segment the company describes as acutely undersupplied. The portfolio has three types of rental stock: **Residential:** dwellings **Lifestyle:** land-lease communities, mainly for over-50s - **Parks**, which are tourist and holiday parks At 30 June 2026 the rental pool was valued at A$701m. Aspen also runs a fast-growing development business. It sells new Lifestyle houses and residential land lots, while keeping the land beneath land-lease homes as a recurring rent-paying site. The model rests on buying property below replacement cost, often from distressed vendors or not-for-profits, and producing new supply cheaply. Management claims a structural cost-of-production advantage over listed peers. In FY26 underlying pre-tax EPS rose 30% to 21.8 cents and NAV (ex-DTL) per security rose 13% to A$2.88. FY27 guidance points to a further 20% EPS increase. --- ### What the company does Aspen Group owns, operates and develops accommodation property across Australia. Its focus is the "value-for-money" end of the housing market. The business has two economic engines. **1. Rentals (recurring income).** - A pool of about 4,222 average dwellings and sites in FY26 (3,984 in FY25). - Three property types: Residential, Lifestyle and Parks. - FY26 rental revenue was A$76.0m, up 13%. - FY26 net rental income (NRI) was A$42.4m, up 21%, at a 56% margin (52% in FY25). - Average weekly gross rent per dwelling or site in FY26 was A$346, up 6%: - Residential A$379 per week (up 4%) - Lifestyle A$223 per week (up 5%) - Parks A$380 per week (up 11%) **Source: FY26 Results Announcement:** 2. Development (transactional profit plus annuity creation). - Aspen builds and sells new transportable or modular-style Lifestyle houses on land-lease sites. The FY26 average price was A$469k. - It also sells residential land lots. The FY26 average price was A$341k, up 51%. - FY26 development revenue was A$65.2m, up 65%. - FY26 realised development profit was A$21.7m, up 71%. - FY26 development margin was 33% and return on invested capital (ROIC) was 20%. - Every Lifestyle house sold produces a development profit and a new land-lease site. That site then pays ground rent (about A$223 per week) to Aspen for the long term. - Management states that realised development profit from Lifestyle house sales exceeded the total cost of producing the newly leased land sites. This "releases equity and increases debt funding capacity" (FY26 Results Announcement). ### Revenue model | Revenue type | Character | FY26 revenue (A$m) | Share of FY26 total | |---|---|---|---| | Residential, Lifestyle and Parks rent, plus ancillary income and deferred management fees (DMF) | Recurring rental / service (short-stay Parks are hospitality-like) | 76.0 | 54% | | Development sales (Lifestyle houses, residential land) | Transactional product sales | 65.2 | 46% | | Total (management basis) | — | 141.2 | 100% | *Source: FY26 Results Announcement. The total is the sum of the rental and development revenue disclosed. For FY25, the management-basis sum (A$67.4m + A$39.5m = A$106.9m) matches statutory revenue from ordinary activities of A$106.917m exactly.* There is no subscription, licensing or IP-based revenue. Historically Aspen also earned funds management fees from unlisted vehicles such as the Aspen Parks Property Fund. Those vehicles have been wound down or absorbed, and the current disclosures do not present funds management as a reported revenue line. ### Value chain position Aspen is vertically integrated across: - Site acquisition, typically opportunistic, below replacement cost, often from liquidators, mortgagees or not-for-profits - Planning and development approvals - Civil works - Procurement and placement of homes - Sales - Ongoing property and community management - Short-stay park operations It is internally managed, with no external manager fee leakage. That arrangement dates from the 2019 decision to remain internally managed. ### Customer types and end-markets | Customer type | Product | Notes | |---|---|---| | Lower-to-middle-income renting households (income below A$100k) | Residential leases | Rents are generally about 10% below market. The bottom 40% of households can afford only about 10% of advertised rentals, per Aspen's analysis in the FY26 announcement. | | Over-50s and retirees, often on the Age Pension, downsizing | Lifestyle land-lease homes plus ground rent | Weekly land-lease costs are below the Commonwealth Rent Assistance cap for pensioner couples, per The Weekly SOURCE (May 2025). | | Corporate tenants housing regional workforces | Furnished, serviced build-to-rent houses (Australind, WA) | FY26 announcement cites "strong corporate demand". | | Tourists, holidaymakers, workers | Short-stay park cabins and sites | Seasonal, weather-exposed | | Retirement village residents | Legacy retirement village (RV) licences with DMF | Acquired in ACH and ECH portfolios; being converted to residential leases on vacancy | | Owner-occupier land buyers | Residential land lots | Mount Barker (SA), Ravenswood (WA), Coorong Quays (SA) and others | ### Company's own description Aspen describes itself as: - A specialist provider of quality rental accommodation on competitive terms - A proven low-cost producer - Offering attractive rents and prices to customers while generating high returns for securityholders *Paraphrased from the May 2025 Equity Raising Presentation and the FY26 materials.* The FY26 results headline was "Open Road Ahead – Upgraded FY27 Guidance and New Development Approvals". ### Independent characterisation Aspen is best understood as a hybrid of three businesses: - A small-cap residential and land-lease REIT - A modest regional hospitality (parks) operator - A capital-light-per-site developer Its development pipeline is carried at only about A$35k per approved or planned site (FY26), well below the end value of a leased land-lease site. That gap is the core of its NAV accretion. The group differs from larger land-lease peers in several ways: 1. It has much lower price points (A$469k average house versus an Australian average dwelling price of about A$1.11m, per ABS March 2026 as cited by Aspen). 2. It values leased sites at a higher capitalisation rate. Aspen uses a weighted average capitalisation rate (WACR) of 6.4% on newly leased Lifestyle sites, versus 5.00–5.25% that it says some competitors use. This makes its book values comparatively conservative. 3. It is willing to recycle capital opportunistically across property types and states. Earnings are increasingly development-weighted. FY27 guidance implies realised development profit of A$33m against NRI of A$44m. That raises cyclicality relative to Aspen's history as a rent-collector.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2001
Surry Hills, Australia
Capex

Capex

Premium
Food & Beverages

| Metric | FY2023 | FY2024 | FY2025 | |---|---|---|---| | Employees (headcount) | — | — | — | Headcount is not disclosed in any source retrieved. The annual report ("Memoria") and sustainability disclosures filed with the CNV are the expected source. Capex S.A. is a mid-sized, family-controlled Argentine integrated energy company that couples upstream oil and gas production with power generation. Its defining asset is the Agua del Cajón complex in Neuquén, where self-produced gas feeds a 672 MW combined-cycle thermal plant and an LPG plant, giving Capex a rare degree of vertical integration among Argentine independents. Since 2021 the centre of gravity has shifted toward oil: around four-fifths of revenue now comes from oil and gas, with heavy crude from Pampa del Castillo (Chubut) exported to Brazil and the US. Capex is also an early Argentine mover in renewables and hydrogen, operating two Patagonian wind farms, a 20 MW solar park, and a hydrogen/oxygen pilot plant since 2008. Its growth vector is Vaca Muerta shale at Agua del Cajón, developed with Trafigura and SLB. The central investment question is refinancing a concentrated 2026–2027 debt maturity wall while funding that growth. --- ### What the company does Capex operates, together with its subsidiaries Servicios Buproneu S.A. (SEB), Hychico S.A., E G WIND S.A. and 4SOLAR S.A., across four activities, as described by FIX SCR from Capex's filings (Dec 2025): 1. **Exploration, production and marketing of oil and gas** — operator of six producing blocks in Neuquén, Río Negro and Chubut. 2. **Thermal power generation** — the Central Térmica Agua del Cajón (CT ADC), a 672 MW plant with a 371 MW open-cycle section and a 301 MW combined-cycle section. 3. **Gas processing and liquids separation** — an LPG plant (owned via SEB, 95%) at Agua del Cajón with 2.4 million m³/day of processing capacity that extracts propane, butane and stabilised gasoline. 4. **Renewables** — wind power (Diadema I and II in Chubut), hydrogen-blended power generation and oxygen sales (Hychico), and solar power (La Salvación, San Luis; Agua del Cajón solar under development). ### Company's own description The company describes itself in its capital-markets offering documents as an Argentine integrated energy company engaged in hydrocarbon exploration and production, thermal and renewable power generation, and hydrogen production (as reproduced in placement announcements for its Class III–XII notes, 2023–2025). Market-data providers summarise Capex's reporting segments as Oil and Gas, Electricity ADC, LPG, Energy DEEF (wind), Hydrogen Energy and Oxygen (TradingView company profile, derived from Capex's segment note). ### Business and revenue model | Revenue stream | Customer | Pricing basis | Share of FY2025 revenue | |---|---|---|---| | Crude oil — export | Trafigura Ltd, BP Oil Supply Co, Refinaria de Mataripe (Brazil); destinations Brazil and USA | Brent-linked export parity | ~33% of consolidated revenue (≈50% of O&G segment) | | Crude oil — domestic | Raízen Argentina, Trafigura Argentina | Domestic price, converging to export parity | Included in O&G 77% | | Gas (own fuel recognised by CAMMESA) | CAMMESA (wholesale market administrator) | USD-denominated at Plan GasAr prices | Included in O&G 77% | | Thermal power (capacity + energy) | CAMMESA | Regulated "Energía Base" remuneration, adjusted by successive Secretariat of Energy resolutions | Energy segment 17% | | LPG (propane, butane) | Export: Lipigas, Gasco GLP (Chile). Domestic: Italgas, IPSA, Cañuelas Gas, Alpes Energy, Naturgy Gas | Market / export prices | 4% | | Wind power | CAMMESA under long-term PPAs (Diadema I: USD 115.896/MWh, 15 years; Diadema II: USD 40.27/MWh, 20 years, plus incentives) | USD PPA | 2% | | Solar power | Private offtakers under MATER (term market) supply contracts | Contracted USD prices (terms not disclosed) | In "Other"/renewables | | Oxygen | Industrial-gases market | Market price | ~0% | Source: FIX SCR, 1 Dec 2025, segment split for the 12 months to April 2025. The revenue model is almost entirely commodity product sales and regulated/contracted power sales; there is no subscription, licensing or services revenue of significance. The export share of revenue was 43% (FY2022), 47% (FY2023), 45% (FY2024) and 35% (FY2025) (FIX SCR, Dec 2025), providing natural USD hedging. ### Value-chain position Capex sits in upstream (E&P) and midstream processing (LPG) and generation (power). The integration loop is: Agua del Cajón gas → LPG plant (liquids stripped and sold) → residual dry gas burned in CT ADC → electricity sold to CAMMESA. FIX notes that Capex directs all of its gas output to CT ADC and the LPG plant, which turns gas monetisation into a power-sales question rather than a gas-marketing one. Capex has no refining or retail fuel distribution. Crude is evacuated via Oldelval pipeline capacity of 651 m³/d (4,095 bbl/d) and stored/exported via 3,906 m³ (25 kbbl) at Oiltanking Ebytem, plus 300 m³/d of pre-expansion open-access capacity (FIX SCR, Dec 2025). ### Independent characterisation Capex is best understood as a conventional-basin oil producer with a captive gas-to-power business attached and a Vaca Muerta growth option. The power plant was historically the earnings anchor; since FY2022 the export-oriented heavy-crude business in Chubut and the oil-weighted shale pads at Agua del Cajón have dominated. Its strategic dilemma is that its largest oil asset (Pampa del Castillo, mature conventional) has high unit costs (lifting cost USD 24.6/boe; all-in about USD 39.5/boe including SG&A and royalties at April 2025), while its growth asset (Vaca Muerta at ADC) requires capital it is funding through partner carry (Trafigura, SLB) and local-market debt.

Revenue$0.3B
EmployeesN/A
Market CapN/A
Founded1988
United States, North America
FACC

FACC AG

Premium
Aerospace

| Metric | FY2023 | FY2024 | FY2025 | |---|---|---|---| | Employees (FTE, year-end) | 3456 | 3850 | 3907 | | Employees (headcount, year-end) | not publicly disclosed in reviewed docs | 4039 | 4050 | At 30 June 2026 FTE reached 4,078 (H1 2026 report), +235 FTE year-on-year (H1 2025: 3,843). FACC AG is an Austrian Tier-1/Tier-2 aerospace supplier specialised in fibre-reinforced composite lightweight systems, majority-owned by China's state aerospace group AVIC since 2009 and listed in Vienna since 2014. It designs, certifies, manufactures and repairs aerostructures (control surfaces, fairings, wing elements), engine and nacelle components in the bypass airflow, and complete floor-to-floor cabin interiors for commercial jets and business aircraft. Airbus generates roughly 52% of revenue, with the A320 family alone near 39%; business jets contribute 17–18%, positioning FACC as a claimed world leader in mid-size business-jet interiors. After a decade of low margins, a cyber-fraud crisis (2016) and the pandemic, the company delivered record 2025 revenue of EUR 984.4m and EBIT of EUR 42.3m, and is guiding to first-time revenue above EUR 1bn in 2026. Its investment case rests on the narrowbody/widebody rate ramp, the CORE efficiency programme, a low-cost Croatian plant, and an FY2027 EBIT-margin target of 8–10%. --- ### What the company does FACC develops, produces and maintains lightweight components and systems for aircraft, predominantly from carbon- and glass-fibre composites, integrating metallic parts (titanium, high-alloy steels, aluminium) and delivering ready-to-install assemblies to OEM final assembly lines (H1 2026 report, Note 1). Activities span the full product lifecycle: design (EASA Part 21/J design organisation, including repairs, modifications and Supplemental Type Certificates), production (EASA Part 21/G) and maintenance/repair (EASA, FAA, CAAC and UK CAA Part 145) (AR 2025, "Our Range of Services"). ### Company's own description (AR 2025, paraphrased) The company describes itself as a one-stop shop whose certified solutions in Aerostructures, Engines & Nacelles and Cabin Interiors are installed in thousands of aircraft and drones operated by all major OEMs and fleet operators, from business jets to short-, medium- and long-haul commercial aircraft and logistics/passenger drones. It emphasises that its triple competence (design–production–maintenance) lets it repair parts others would scrap, and its boilerplate states that an aircraft carrying FACC technology takes off every second worldwide. ### Business and revenue model | Revenue type | FY2024 (EUR m) | FY2025 (EUR m) | Share FY2025 | Source | |---|---|---|---|---| | Product sales | 803.7 | 907.0 | 92.1% | AR 2025, ESRS SBM-1 | | Development services and other services | 80.8 | 77.4 | 7.9% | AR 2025, ESRS SBM-1 | | Total | 884.5 | 984.4 | 100% | AR 2025 | The model is overwhelmingly build-to-print / build-to-spec series manufacturing under long-term program contracts (life-of-program supply agreements typical of the industry), supplemented by customer-funded non-recurring engineering (development services), aftermarket repair/MRO and spares. There is no material subscription or licensing revenue (not disclosed as a category). Revenue is largely USD-denominated while a significant share of costs is in EUR, creating a structural currency exposure that the company hedges (at least 80% of expected 12-month net USD cash flows, extendable to 36 months) (H1 2026 report, Notes 10–12). ### Value-chain position FACC sits between material suppliers (carbon fibre/prepreg producers such as Toray and Hexcel, named in AR 2025) and airframe/engine OEMs and Tier-1 system integrators (Airbus, Boeing, Embraer, Bombardier, COMAC, Rolls-Royce, Pratt & Whitney, Collins, Safran, among others named in company releases). In Aerostructures it acts mainly as a Tier-1 supplier of secondary structures and control surfaces with ambitions in primary structures; in Engines & Nacelles it supplies engine OEMs and nacelle integrators (Collins and Safran explicitly named as nacelle customers in AR 2025); in Cabin Interiors it delivers complete integrated interiors (linings, overhead bins, cargo and cockpit linings) direct to OEMs, including business-jet OEMs. ### Customers and end-markets | Customer / platform exposure | Share of group revenue | Period | Source | |---|---|---|---| | Airbus (all programs) | approx. 52% | H1 2026 | H1 2026 report | | Airbus A320 family | approx. 39% | H1 2026 | H1 2026 report | | Business jets (all OEMs) | approx. 17% (18% in FY2025 deck) | H1 2026 / FY2025 | H1 2026 report; FY2025 presentation | | Airbus A350 | approx. 12% | H1 2026 | H1 2026 report | | COMAC (C909, C919) | third-largest customer within Cabin Interiors | H1 2026 | H1 2026 report | | Largest single customer receivable | EUR 139.8m | 30 Jun 2026 | H1 2026 report, Note 14 | End-markets: commercial narrowbody and widebody air transport (dominant), business aviation, regional aviation, engines aftermarket/MRO, and emerging Advanced Air Mobility (eVTOL/drones: Archer Aviation, Eve Air Mobility; historically EHang). Defence is not a disclosed end-market. ### Independent characterization FACC is a mid-cap, capital-intensive, labour-intensive composites converter whose economics are driven by (i) Airbus narrowbody and A350 build rates, (ii) its ability to pass raw-material, energy and Austrian wage inflation through to OEMs with strong bargaining power, and (iii) the share of production it can shift to low-cost geographies (Croatia, India via partners, China). Its historic weakness was a thin margin (EBIT margin below 3.5% every year from 2021 to 2024), which management is now addressing through structural cost-out rather than volume alone. The AVIC ownership provides balance-sheet comfort and preferential access to COMAC, but also introduces governance and geopolitical considerations that weigh on Western investor perception.

Revenue$1.1B
Employees3,907
Market CapN/A
Founded1989
United States, North America
Bajaj

Bajaj Healthcare Ltd

Premium
Healthcare

Bajaj Healthcare is a Thane-based, promoter-controlled, small-cap Indian pharmaceutical manufacturer. It is vertically integrated across intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations, with a legacy in nutraceutical APIs (ascorbates, amino acids). FY26 revenue was INR 6,110 M. Roughly 83% of revenue comes from APIs and intermediates, and exports account for about 31%, sold into more than 60 countries. The company is repositioning from a price-sensitive domestic bulk-drug supplier toward three areas: regulated-market API exports (EU/UK CEP filings and CDMO contracts covering about 30 molecules), "first-in-India" CNS molecules (Cenobamate, launched September 2026; Suvorexant and Pimavanserin in the pipeline), and specialty adjacencies (government opiate processing, the Bajaj Oncocare oncology platform, and a planned peptide plant). A 2024–26 preferential equity raise of INR 204.97 Cr de-levered the balance sheet to 0.47x debt/equity. Execution on working capital remains the principal credit and equity debate: the cash conversion cycle exceeds 250 days. --- ### Company's own description In its filings and investor releases, the company calls itself one of India's leading manufacturers of APIs, intermediates and formulations. Its corporate summary adds that it is a large-scale, vertically integrated manufacturer serving quality-conscious customers, making APIs, intermediates, finished dosage forms and nutraceuticals for the pharmaceutical, nutraceutical and food industries [AR-FY25; PR-Q2FY27 boilerplate]. The FY25 Directors' Report defines the business as manufacturing and exporting APIs and formulations, plus allied activities [AR-FY25]. ### Independent characterization Bajaj Healthcare is best understood as a mid-tier Indian bulk-drug (API) house in transition. It has four distinct revenue engines: 1. **Domestic API sales (52% of FY26 revenue).** Commodity and semi-specialty APIs and intermediates sold to Indian formulators. This is volume-driven and exposed to Chinese-led price erosion. Management repeatedly cited domestic API price erosion as the main FY26 headwind [PR-Q4FY26]. 2. **API exports (31% of FY26 revenue).** Sales into regulated (EU, UK, Australia via TGA-approved Vadodara site, LATAM) and semi-regulated markets. These rest on CEP/DMF filings and long-tenor CDMO supply contracts with UK/EU clients covering about 30 molecules. This was the fastest-growing line: +51.6% in FY26 [PR-Q4FY26]. 3. **Formulations (17% of FY26; 23.7% in Q2 FY27).** Branded and generic finished doses from the Manjusar (Vadodara) WHO-GMP plant. Sales go to institutional and government buyers (the company cites Indian Railways, Defence and government healthcare programmes [CALL-Q1FY27]), to marketing partners (Cenobamate is sold through eight partners [PR-Q2FY27 coverage]), and through the Bajaj Oncocare oncology platform launched in 2024. 4. **Specialty and regulated niches (embedded in the lines above; not separately reported).** These comprise: opium and poppy-straw alkaloid processing for the Government of India at Savli (capacity about 250 MT opium gum and about 2,500 MT poppy straw); licensed nutraceutical ingredients such as Magtein (Magnesium L-Threonate, exclusive Indian rights from Threotech LLC); and one-time technical know-how income. The reversal of a INR 332.5 M know-how fee in Q4 FY26 shows the risk in that last item. ### Revenue model mix | Revenue model | Share | Evidence | |---|---|---| | Product sales (APIs, intermediates, formulations) | ~95–100% of revenue from operations | Revenue breakup in all investor releases is product-based | | Contract manufacturing (CDMO) | Not separately disclosed; embedded in API exports | CDMO contracts for 15 molecules (27 Feb 2024) and 15 more (9 Dec 2024) with UK/EU clients | | Licensing / technical know-how fees | Episodic; FY26 saw INR 332.47 M of previously recognized income reversed | [RES-Q4FY26] exceptional item | | Job-work / government processing (opiates) | Not separately disclosed | Government of India tenders executed at Savli | | Subscription / services | None | — | ### Value-chain position The company sits upstream to mid-stream. It makes key starting materials and intermediates and sells APIs to other formulators, while also forward-integrating into finished doses. Its Tarapur intermediate units (now largely discontinued and divested) once supplied captive inputs to the Savli and Panoli API plants. That backward integration was deliberately reduced in 2023–26 because the Tarapur units were loss-making. ### Customer types and end-markets | Customer type | End-market | Notes | |---|---|---| | Indian formulators | Domestic generics | Largest revenue pool; price-sensitive | | Regulated-market generic companies (EU/UK) | European generics | Served via CEPs (12 filed: 8 approved, 4 under review as of Jul 2026) | | CDMO clients (UK/EU) | Innovator/generic supply chains | ~30 molecules under contract | | Australia / NZ / South Africa | Regulated generics | Enabled by TGA approval of the Vadodara site; management has flagged pipeline deals | | LATAM and rest of world | Semi-regulated generics | Cited as a FY26 growth contributor | | Government of India / institutions | Opiates processing; institutional formulations | Railways, Defence, government programmes | | Nutraceutical and food companies | Vitamins, minerals, amino acids | Legacy ascorbate franchise; Magtein licence | | Indian prescribers via marketing partners | CNS specialty formulations | Cenobamate (Sept 2026 launch), Suvorexant, Pimavanserin |

Revenue$0.1B
EmployeesN/A
Market CapN/A
Founded1993
Thane, India
Boise

Boise Cascade

Premium
Manufacturing & Construction

Revenue$6.4B
EmployeesN/A
Market CapN/A
Founded1957
United States, North America
Kronospan

Kronospan

Premium
Manufacturing & Construction

| Field | Kronospan Limited (UK) | Kronospan Group (context) | |---|---|---| | Legal name | KRONOSPAN LIMITED | Multiple entities; holding entity cited as Kronospan Holdings P.L.C. in EU merger filing (2022) | | Former names | None shown on register | Group legal structure not publicly consolidated | | Founding year | Incorporated 11 June 1970 (Companies House); Chirk site purchased 1970 (WBPI) | 1897, a single sawmill in Lungötz, Austria (Kaindl family) | | Incorporation jurisdiction | England & Wales | Various; Austria historically; Cyprus/Malta holding entities reported | | Headquarters | Maesgwyn Farm, Holyhead Road, Chirk, Wrexham LL14 5NT, Wales | Operational leadership historically associated with Austria and Switzerland; no single published group HQ address | | Stock exchange / ticker | None (private) | None (private) | | ISIN / CUSIP | Not applicable | Not applicable | | Fiscal year end | 30 September | 30 September (UK and Latvian entities; group-wide FYE not published) | | Employees (latest) | 677 average staff, FY2024 (WBPI reporting on accounts); company states over 650 at Chirk (Nov 2025 press release) | "Over 14,000" (company profile text); Wikipedia cites over 15,000 (2021) | | Employee trend | FY2023: 660 → FY2024: 677 (WBPI) | Not consistently disclosed | | Auditor | — | n.d. | | Market capitalisation | Not applicable (private) | Not applicable (private) | | Website | kronospan.com/en_UK | kronospan.com | | SIC code | 16210, manufacture of veneer sheets and wood-based panels | — | | Latest accounts | Full accounts to 30 September 2025, filed 9 June 2026 | n.d. | | Latest confirmation statement | 21 August 2026, no updates (filed 25 August 2026) | — | Kronospan Limited operates one of the UK's largest integrated wood-based panel complexes at Chirk, on the Wales–England border. It converts virgin roundwood, sawmill residues and post-consumer recycled timber into raw and decorative panels for the UK furniture, kitchen, construction and DIY markets. Its output includes particleboard, MDF, P5 flooring board, melamine-faced panels, laminate flooring, worktops and sawn timber. The site is vertically integrated, with in-house resin production, sawmilling and energy generation. That model gives Kronospan scale-cost advantages over importers and smaller domestic rivals. It also exposes the company to cyclical housing and furniture demand, energy and resin input costs, and continuous scrutiny of its environmental impact on a closely neighbouring town. Kronospan Limited is a subsidiary of the privately held Kronospan group, one of the world's largest panel producers. The parent operates more than 40 production sites, which gives the UK business technical support, decor libraries and procurement scale that a stand-alone company could not match. --- ### What the company does Kronospan Limited manufactures and sells wood-based panels and value-added panel products from a single integrated site at Chirk. The Welsh Minister's visit release of 1 November 2025 lists the product scope as particleboard, MDF, P5 flooring board, melamine-faced wood-based panels, laminate flooring, worktops and sawn timber (Source: kronospan.com, "Kronospan UK welcomes Welsh Minister", 1 Nov 2025). The site also has chemical capability. The group directory lists Kronospan Limited under both "Production Sites" and "Chemical Plants" in the UK, and WBPI has documented resin kettles and reactors at Chirk (Sources: group site directory reproduced by forestsource.io, Apr 2026; WBPI site feature). ### Company's own description The group describes itself as a global leader in particleboard, MDF, laminate flooring and UF/MUF/MF resins, and as Europe's leading OSB producer. It also produces decorative and specialty paper, melamine-faced panels, worktops, wall panels, window sills, lacquered HDF, compact boards and HPL (Source: Kronospan corporate profile text on third-party directories, citing kronospan.com). Kronospan Limited does not publish a separate narrative annual report. Its strategic report sits within statutory accounts filed at Companies House. Commentary on the FY2024 accounts, as reported by WBPI, described the period as competitive, with selling prices eroded by high interest rates and cost-of-living pressure. It also noted that investment activity had been scaled back after years of strategic investment (Source: WBPI, Oct 2025). ### Business and revenue model | Dimension | Characterisation | Evidence basis | |---|---|---| | Revenue model | Almost entirely product sales (manufactured goods); no material subscription or licensing revenue disclosed | Product-only scope in company releases | | Product vs. service mix | ~100% product; minor services (cutting, sampling, design-centre specification support at group level) | Group design-centre network (Milan, Athens, Casablanca, London events) | | Value-chain position | Upstream/midstream: forestry and sawmilling → resin chemistry → raw board → surface finishing (MFC, laminate) | UK sister entities: Eskdalemuir Forestry Ltd, Kronospan Sawmilling Ltd, Silva Recycling Ltd | | Customer types | Furniture and kitchen manufacturers, panel distributors and merchants, DIY retail, construction and housebuilding supply chain | Shropshire Star (2017) cites construction, furniture and DIY; Benelux, France and Germany export markets | | End markets | Residential construction and RMI, furniture, kitchens, shopfitting/retail interiors, flooring | Group trade-show focus (DOMOTEX, EuroShop, Holz-Handwerk 2026) | ### Independent characterisation Kronospan Limited is a commodity-cyclical, capital-intensive process manufacturer. Profitability depends on the spread between panel selling prices and the combined cost of wood fibre, urea and melamine resins, and energy. The FY2023 to FY2024 swing shows how high that operating leverage is: revenue fell about 13% while pre-tax profit fell more than 98%. Its structural advantages are domestic production in a net-importing UK market, integrated recycled-wood sourcing, and in-house resins. Its structural vulnerabilities are a single-site concentration, a site that sits right next to housing, and price competition from continental imports, including imports from its own group's EU plants.

RevenueN/A
Employees677
Market CapN/A
Founded1897
United States, North America
Lindner

Lindner Group

Premium
Manufacturing & Construction

RevenueN/A
Employees8,000
Market CapN/A
Founded1965
United States, North America
LeonardoDRS

Leonardo DRS

Premium
Aerospace

Leonardo DRS — AnD

Revenue$3.6B
EmployeesN/A
Market CapN/A
Founded1968
United States, North America
Sanmina

Sanmina Corporation

Premium
Aerospace

Sanmina Corporation — AnD

Revenue$8.1B
EmployeesN/A
Market CapN/A
Founded1980
United States, North America
General

General Dynamics Mission Systems

Premium
Aerospace

General Dynamics Mission Systems — AnD

RevenueN/A
Employees13,000
Market CapN/A
Founded1999
United States, North America
Boehringer

Boehringer Ingelheim

Premium
Healthcare

Boehringer Ingelheim — Healthcare

Revenue$22.3B
EmployeesN/A
Market CapN/A
Founded1885
United States, North America
Dassault

Dassault Systèmes SE

Premium
ICT

Dassault Systèmes SE — ICT

Revenue$5.5B
EmployeesN/A
Market CapN/A
Founded1981
United States, North America
Buzzi

Buzzi

Premium
Chemicals & Materials

Buzzi — CNM

Revenue$4.0B
EmployeesN/A
Market CapN/A
Founded1907
United States, North America
REV

REV Group

Premium
Automotive

REV Group — Auto

Revenue$2.3B
EmployeesN/A
Market CapN/A
Founded2010
United States, North America
Morita

Morita Holdings Corporation

Premium
Automotive

Morita Holdings Corporation — Auto

Revenue$0.8B
EmployeesN/A
Market CapN/A
Founded1907
United States, North America
Hella

Hella

Premium
Automotive

Hella — Auto

RevenueN/A
Employees37,448
Market CapN/A
Founded1899
United States, North America
Synthomer

Synthomer PLC

Premium
Chemicals & Materials

Synthomer PLC — CNM

Revenue$2.2B
EmployeesN/A
Market CapN/A
Founded1863
United States, North America
Labcorp

Labcorp

Premium
Healthcare

Labcorp — Healthcare

Revenue$14.9B
EmployeesN/A
Market CapN/A
Founded1978
United States, North America
LionEnergy

Lion Energy

Premium
Energy & Power

### Core Identification Data | Field | Detail | Source | |---|---|---| | Legal name | Lion Energy Limited | ASX announcements 2026 | | ABN | 51 000 753 640 | ASX announcement, 29 Jun 2026 | | Former names | Kalgoorlie Resources NL (ASX: KGR) until 10 Dec 1998; Kalrez Energy NL (ASX: KRZ) until 31 Jan 2001; Kalrez Energy Limited until 10 Oct 2003; thereafter Lion Energy Limited | Market Index corporate history (Morningstar) | | Year of incorporation | 1970 | S&P Global company profile | | ASX listing date | 15 February 1972 | Market Index | | Incorporation jurisdiction | Australia (Western Australia-based public company) | Company filings | | Headquarters address | Suite 1, 295 Rokeby Road, Subiaco WA 6008, Australia (older materials cite Suite 7 at the same address) | ASX announcement, 29 Jun 2026; company website | | Telephone / email | +61 8 9211 1500 / info@lionenergy.com.au | ASX announcement, 29 Jun 2026 | | Exchange and ticker | Australian Securities Exchange: LIO (sole listing) | ASX | | ISIN | AU000000LIO7 (standard ASX ISIN construction; confirm with registry) | — | | CUSIP | Not applicable (no US listing) | — | | Fiscal year end | 31 December | S&P Global; statutory accounts released 31 Mar 2026 | | Share registry | Computershare | Market Index | | Auditor | Hall Chadwick WA Audit Pty Ltd | Market Index | | Employees (latest) | Not publicly disclosed. The company runs a small Perth corporate team plus a drilling, HSE, procurement and logistics team in Jakarta (Bula Karang-1 update #1, 25 Feb 2026) | ASX announcements | | Employees (3-year trend) | Not publicly disclosed | — | | Shares on issue | 452.18 million (FY2024, FY2025 and 30 June 2026) | S&P Global; Morningstar | | Market capitalisation (current) | A$8.14 million at A$0.018 (9 October 2026 close) | StockAnalysis.com | | 52-week trading range | A$0.009 – A$0.026 | StockAnalysis.com | | Industry classification | Energy — Oil & Gas Exploration & Production | S&P Global | Lion Energy is a micro-cap Perth-based upstream oil and gas company. After a failed diversification, it has returned to a single-asset exploration model in eastern Indonesia. Its core asset is a 45% operated interest, held through subsidiary Balam Energy Pte Ltd, in the East Seram Production Sharing Contract (PSC) on Seram Island in Maluku province. Partner OPIC East Seram Corporation, a subsidiary of Taiwan's state-owned CPC Corporation, holds the other 55%. The near-term investment case rests almost entirely on the Bula Karang-1 exploration well. The well has a P50 prospective resource of 12 million barrels and a 38% geological chance of success, and OPIC funds 88% of costs up to US$5.6 million. From 2021 to 2026 Lion pursued green hydrogen in Australia, culminating in the Port of Brisbane hub. It terminated that project in May 2026 and has now exited hydrogen entirely. With under A$1 million of cash at June 2026, Lion is a high-risk, binary, event-driven exploration stock. --- ### What the Company Does Lion Energy explores for, appraises and seeks to develop conventional oil and gas in eastern Indonesia, centred on Seram Island in the Seram Basin. In practice, the company today is: 1. **An operator of an exploration-stage PSC.** Balam Energy Pte Ltd, a wholly owned Lion subsidiary, is operator of the East Seram PSC with a 45% participating interest. S&P Global reports the PSC area as about 1,300 km². 2. **A project manager for a single exploration well.** Lion runs Bula Karang-1, a deviated well drilled from an onshore pad to an offshore reef target in Bula Bay. It contracts a third-party rig (Silver City Drilling's SCD-20) and specialist services such as directional drilling, cementing, drilling fluids and wireline. 3. **A residual holder of legacy positions.** Lion agreed in September 2025 to sell its 2.5% minority interest in the producing Seram (Non-Bula) PSC for about US$1.2 million. It retains holding rights to the now-dormant Port of Brisbane hydrogen site, and has sold the related equipment. ### Company's Own Description The website "About Us" page describes Lion as a recently revamped and refocused ASX-listed oil and gas company focused on Southeast Asia, and specifically on the Seram Basin of East Indonesia. It characterises that basin as immature yet proven, with existing oil and gas export infrastructure serving the producing Oseil field. The company also claims: - the largest land position on Seram Island; - long PSC tenure under newer fiscal terms; - that the Manusela pre-Tertiary play (hosting Lofin and Oseil) has had six targeted exploration wells, all discoveries; - about 700 million barrels of oil equivalent (mmboe) of upside within East Seram. A separate "Company Overview" page, which still reflects the 2021–2025 strategy, presents Lion as applying upstream skills to green hydrogen in Australia. ASX announcements in 2026 describe Lion more narrowly. The standard "Lion at a glance" box calls it an ASX-listed oil and gas E&P company with a conventional PSC on Seram Island, Indonesia, drilling an oil exploration well in Q3 2026. ### Business Model and Revenue Model | Dimension | Characterisation | |---|---| | Model type | Pre-revenue exploration (project-generation and farm-out model) | | Product vs service mix | Historical revenue came from Lion's share of crude oil sales from the 2.5% Seram (Non-Bula) interest and minor other income. No subscription or licensing revenue. | | Revenue scale | A$0.14M in FY2025; A$0.10M in FY2024 (S&P Global). Morningstar reports FY2024 trading revenue of A$0.84M; see Section 6 for this discrepancy. | | Value creation mechanism | Acquire acreage cheaply, de-risk with seismic and technical work, farm out to fund drilling, and monetise discoveries through development or sale | | Funding model | Equity placements, convertible notes (A$1.6M issued 2024), asset sales (Seram Non-Bula, US$1.2M), farm-out carries (OPIC funds 88% of Bula Karang-1 up to US$5.6M), and partner payments (DGA and Samsung C&T paid towards hydrogen pre-construction costs) | | Value chain position | Upstream: exploration, appraisal and early development. No midstream or downstream exposure. | | Customer types (if production achieved) | Indonesian crude buyers under PSC lifting arrangements, typically state entities or offtakers via SKK Migas-administered processes. The pricing reference is the Indonesian Crude Price (ICP). | | End-markets | Indonesian and regional Asian crude oil markets | ### Independent Characterisation Lion is best understood as a call option on one well, wrapped in a corporate shell with very limited liquidity. The OPIC farm-out caps Lion's net exposure to about US$0.7 million (12% of the US$5.6 million well cost estimate). Costs above the cap are shared 45/55 between Balam and OPIC. If Bula Karang-1 succeeds, the shallow, near-infrastructure location supports a fast-track extended well test and early production. The company planned the test for November 2026 using a workover rig already in the Bula area. If the well fails, Lion is left with a reduced East Seram position, minimal cash and a convertible note liability, and its strategic future would be uncertain. The five-year hydrogen detour consumed capital and management attention, and ended in a A$3.27 million asset writedown in FY2025. The return to oil exploration reflects capital discipline under duress rather than a strategic choice made from strength.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1970
Subiaco, Australia
AM

AM Technology

Premium
Chemicals & Materials

Company Headquarters: 2000 Founded: UK Workforce: The company has employed more than 100 employees. Company Working: AM Technology (Ashe Morris Ltd) is a UK-based company that designs, manufactures, and sells continuous flow reactors and continuous flow chemical plants for the fine chemical and pharmaceutical industries. The company was founded in 2000 and is headquartered in Runcorn, Cheshire. AM Technology's products are used to produce a wide range of chemicals, including active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals. The company's continuous flow reactors offer a number of advantages over traditional batch reactors, including improved safety, scalability, and efficiency. They are also more environmentally friendly, as they produce less waste and emissions. AM Technology's customers include leading pharmaceutical companies, fine chemical manufacturers, and research institutes around the world. The company has a strong track record of innovation and has developed a number of patented technologies. AM Technology is well-positioned for continued growth in the years to come, as the demand for continuous flow reactors and continuous flow chemical plants continues to grow

RevenueN/A
Employees100
Market CapN/A
FoundedN/A
2000
Ajwa

Ajwa Food Products (I) Pvt. Ltd

Premium
Food & Beverages

Company Headquarters: Gujrat, India Founded: 2010 Workforce: ~NA Company Working: Ajwa Food Products (I) Pvt. Ltd. is one of the leading players offering high-quality products and ingredients in an affordable price range. The company is a privately-held enterprise that is adhered to the policies implemented on the day of incorporation. Ajwa Food Products (I) Pvt. Ltd. has expertise in the production, supply, wholesale, retail, and export of a diversified range of products associated with the food & beverage industry. The products offered by the company are free from GMOs, have no added colors, and are sourced ethically. Ajwa Food Products (I) Pvt. Ltd. also has state-of-art facilities that are integrated with cutting-edge technology to maintain production. The products offered by the company are prepared hygienically and are blended with sugar, pure milk, ghee, dry fruits, and other pure ingredients. Ajwa Food Products (I) Pvt. Ltd. also provides the products in different packaging options. In addition, the company also supplies a wide range of fruits & vegetables, pulses & grains, and spices to different across the globe. Ajwa Food Products (I) Pvt. Ltd. procures high-quality raw materials to produce finalized goods. The company also has very skilled and highly qualified professionals, focused on the maintenance of quality. Apart from that, the company also offers an organic range of products. Ajwa Food Products (I) Pvt. Ltd. has operations in more than 30 nations around the world.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2010
Gujrat, India
Image

Image Laundry Systems

Premium
Equipment & Machinery

Company Headquarters: Thailand Founded: 1997 Workforce: NA Estimated Revenue- US$ 5.75 Mn Company Working: Image Laundry Systems is a family-owned business that is a manufacturer of industrial and commercial laundry equipment engaged in selling laundry equipment for over 40 years. The company exports its products to more than 40 countries globally. The company offers a wide range of products that includes Washer Extractors, Flatwork Ironers, Coin Operated, Tumble Dryers, Feeders, Folders, and Tunnel Washers that are designed by European and American designers. The company has more than 50 laundry products and 10,000 dry-cleaned products. The company serves various industries that include coin laundries, hospitality, commercial linen plants, healthcare, dry cleaning plants, oil field camps, mat rentals, and commercial washers.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1997
Thailand
Fibercon

Fibercon International Inc

Premium
Chemicals & Materials

Company Headquarters: Pennsylvania, United StatesFounded: 1981 Workforce: ~ NA Company Working: Fibercon International Inc. is a company that specializes in the production and distribution of fiber reinforcement solutions for concrete. Fibercon International Inc. is known for its innovative fiber reinforcement products used in the construction industry. They offer a wide range of fiber types, including synthetic macro fibers and steel fibers, designed to enhance the performance and durability of concrete structures. Fibercon's fiber reinforcement solutions are used in various applications such as slabs, shotcrete, precast elements, tunnels, bridge decks, and more. These fibers provide benefits such as increased crack resistance, improved impact resistance, enhanced durability, and reduced maintenance costs.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1981
Pennsylvania, United StatesFounded: 1981

Page 232 of 482

1…231232233…482

Page 232 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo